The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Siblings trying to make US water polo teams for Paris Olympics
Women's Wellness, Beauty Market Glowing Brightly
Shanghai Hosts Tourism Festival to Boost Consumption
Exhibition of Healthcare Services at 2023 CIFTIS
Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
Relocated Villagers in Jinghai District of China's Tianjin Return Home As Flood Recedes
China Beats Japan to Retain Asiad Women's Volleyball Title
National Youth Space Innovation Competition Held in South China
Cruise worker 'murders newborn son on board ship': Shocked co
China Focus: Village Cafe in Qinling Mountains Emerges as Tourism Hotspot
Company wins court ruling to continue development of Michigan factory serving EV industry
First Cyber Security Summit Opens in Tianjin